RU2019100102A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019100102A3 RU2019100102A3 RU2019100102A RU2019100102A RU2019100102A3 RU 2019100102 A3 RU2019100102 A3 RU 2019100102A3 RU 2019100102 A RU2019100102 A RU 2019100102A RU 2019100102 A RU2019100102 A RU 2019100102A RU 2019100102 A3 RU2019100102 A3 RU 2019100102A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351054P | 2016-06-16 | 2016-06-16 | |
| US62/351,054 | 2016-06-16 | ||
| PCT/US2017/037533 WO2017218691A1 (en) | 2016-06-16 | 2017-06-14 | Humanized and chimeric monoclonal antibodies to cd81 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019100102A RU2019100102A (ru) | 2020-07-16 |
| RU2019100102A3 true RU2019100102A3 (enExample) | 2020-10-14 |
Family
ID=60664252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019100102A RU2019100102A (ru) | 2016-06-16 | 2017-06-14 | Гуманизированные и химерные моноклональные антитела против cd81 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10815306B2 (enExample) |
| EP (1) | EP3471762A4 (enExample) |
| JP (1) | JP2019517813A (enExample) |
| CN (1) | CN109414492A (enExample) |
| BR (1) | BR112018076247A2 (enExample) |
| CA (1) | CA3027942A1 (enExample) |
| MA (1) | MA45404A (enExample) |
| RU (1) | RU2019100102A (enExample) |
| WO (1) | WO2017218691A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021150266A1 (en) * | 2020-01-21 | 2021-07-29 | Tavotek Biotherapeutics (Hong Kong) Limited | Agents that interfere with il-1beta receptor signalling |
| WO2024079192A1 (en) | 2022-10-12 | 2024-04-18 | Institut National de la Santé et de la Recherche Médicale | Cd81 as a biomarker and biotarget in t-cell malignancies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| WO2006037604A1 (en) | 2004-10-01 | 2006-04-13 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel antibodies directed to the mammalian eag1 ion channel protein |
| US8034902B2 (en) * | 2005-05-04 | 2011-10-11 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against CD55 and CD59 and uses thereof |
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| US7858752B2 (en) * | 2006-12-05 | 2010-12-28 | Abbott Laboratories | Recombinant antibodies against hepatitis C virus and methods of obtaining and using same |
| WO2011016238A1 (en) * | 2009-08-06 | 2011-02-10 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
| US20140030771A1 (en) | 2010-06-09 | 2014-01-30 | Richard C. Yu | Compositions and methods for increasing oil production and secretion |
| US8440797B2 (en) * | 2010-12-06 | 2013-05-14 | Dainippon Sumitomo Pharma Co., Ltd. | Human monoclonal antibody |
| EP2650367A4 (en) * | 2010-12-06 | 2015-07-08 | Sumitomo Dainippon Pharma Co Ltd | HUMAN MONOCLONAL ANTIBODY |
| US9725517B2 (en) * | 2012-10-26 | 2017-08-08 | Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences | Humanized monoclonal antibodies against the extracellular domain of human death receptor 5 |
-
2017
- 2017-06-14 CA CA3027942A patent/CA3027942A1/en not_active Abandoned
- 2017-06-14 CN CN201780040994.1A patent/CN109414492A/zh active Pending
- 2017-06-14 JP JP2018566226A patent/JP2019517813A/ja active Pending
- 2017-06-14 RU RU2019100102A patent/RU2019100102A/ru not_active Application Discontinuation
- 2017-06-14 BR BR112018076247-4A patent/BR112018076247A2/pt not_active Application Discontinuation
- 2017-06-14 MA MA045404A patent/MA45404A/fr unknown
- 2017-06-14 EP EP17814033.1A patent/EP3471762A4/en not_active Withdrawn
- 2017-06-14 US US16/308,113 patent/US10815306B2/en active Active
- 2017-06-14 WO PCT/US2017/037533 patent/WO2017218691A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3471762A1 (en) | 2019-04-24 |
| EP3471762A4 (en) | 2020-03-11 |
| CN109414492A (zh) | 2019-03-01 |
| BR112018076247A2 (pt) | 2019-03-26 |
| WO2017218691A1 (en) | 2017-12-21 |
| MA45404A (fr) | 2019-04-24 |
| US10815306B2 (en) | 2020-10-27 |
| US20190177425A1 (en) | 2019-06-13 |
| RU2019100102A (ru) | 2020-07-16 |
| CA3027942A1 (en) | 2017-12-21 |
| JP2019517813A (ja) | 2019-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018068177A2 (enExample) | ||
| BR112018003417A2 (enExample) | ||
| BR112019009201A2 (enExample) | ||
| BR112019002665A2 (enExample) | ||
| BR112018004986A2 (enExample) | ||
| BR112019008105A2 (enExample) | ||
| BR112019009263A2 (enExample) | ||
| BR112019001429A2 (enExample) | ||
| BR112019008300A2 (enExample) | ||
| BR112019008318A2 (enExample) | ||
| BR112019000402A2 (enExample) | ||
| BR112018003077A2 (enExample) | ||
| BR212018070320U2 (enExample) | ||
| BR112019008501B1 (pt) | Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador | |
| BR112019003116B1 (pt) | Configuração de símbolo de rajada comum de uplink | |
| BR112019001236B1 (pt) | Método para executar uma função suplementar para uma consulta de linguagem natural apresentada a um aplicativo de orientação de mídia interativa | |
| BR112018075550B1 (pt) | Método para reparo de arquivo de intervalo de bytes, dispositivo de computação e memória | |
| BR112018076493B1 (pt) | Sistemas e métodos para detecção de posição de feixe de luz | |
| BR112018073794B1 (pt) | Partícula, método de geração da partícula, vacina ou composição farmacêutica | |
| BR112018073322B1 (pt) | Método para comunicação sem fio realizado por um equipamento de usuário (ue), método para comunicação sem fio realizado por uma estação base (bs), aparelho para comunicações sem fio, e, memória legível por computador | |
| BR122026002520A2 (pt) | Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno | |
| BR112019006736A2 (enExample) | ||
| BR112019003108A2 (enExample) | ||
| CN303597836S (zh) | 不锈钢板（kb-052） | |
| CN303629183S (zh) | 洗盆（艺术碗a052） |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20211101 |